In our Data Explorer you can see our COVID-19 vaccination data — you can also visualize the latest data on confirmed cases, deaths, and testing.
→ Open the Data Explorer in a new tab.
Select a group of countries at once: all European countries, 30 largest countries; EU; Americas; OECD.
To bring this pandemic to an end, a large share of the world needs to be immune to the virus. The safest way to achieve this is with a vaccine. Vaccines are a technology that humanity has often relied on in the past to bring down the death toll of infectious diseases.
Within less than 12 months after the beginning of the COVID-19 pandemic, several research teams rose to the challenge and developed vaccines that protect from SARS-CoV-2, the virus that causes COVID-19.
Now the challenge is to make these vaccines available to people around the world. It will be key that people in all countries — not just in rich countries — receive the required protection. To track this effort we at Our World in Data are building the international COVID-19 vaccination dataset that we make available on this page.
- Data sources: at the end of this page you find a detailed list of all our country-specific sources.
- Open access: as with all of our data, we are making this dataset openly available, so that everyone can check and use the data that we bring together. You find the vaccination data in our daily-updated repository on GitHub.
Country-by-country data on COVID-19 vaccinations
This page has a number of charts on vaccination. In the box below you can select any country you are interested in — or several, if you want to compare countries.
All charts on this page will then show data for the countries that you selected.
The following map and chart show the number of COVID-19 vaccination doses administered per 100 people within a given population. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime as several available COVID vaccines require multiple doses.
The following chart shows the total number of COVID-19 vaccination doses administered. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).
The following chart shows the share of the total population that has received at least one dose of the COVID-19 vaccine. This may not equal the share that are fully vaccinated if the vaccine requires two doses. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.
The following chart shows the total number of people that have received at least one dose of the COVID-19 vaccine. This may not equal the number that are fully vaccinated if the vaccine requires two doses. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.
The following chart shows the share of the total population that has been fully vaccinated against COVID-19. This represents the share that have received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.
This data is only available for countries which report the breakdown of doses administered by first and second doses.
The following chart shows the total number of people that have been fully vaccinated against COVID-19. This represents the number that have received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.
This data is only available for countries which report the breakdown of doses administered by first and second doses.
The metrics above provide the total number of doses administered — the cumulative doses over time.
The following chart shows the daily number of COVID-19 vaccination doses administered. This is shown as the rolling seven-day average. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).
The following chart shows the daily number of COVID-19 vaccination doses administered per 100 people. This is shown as the rolling seven-day average. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).
This interactive chart maps government policies on COVID-19 vaccination. Note that this only tracks policies on the availability of vaccinations. It does not track the number of people who have been vaccinated.
Countries are grouped into six categories:
- No availability
- Availability for ONE of following: key workers/ clinically vulnerable groups / elderly groups
- Availability for TWO of following: key workers/ clinically vulnerable groups / elderly groups
- Availability for ALL of following: key workers/ clinically vulnerable groups / elderly groups
- Availability for all three plus partial additional availability (select broad groups/ages)
- Universal availability
Vaccination policy data is sourced from the Oxford Coronavirus Government Response Tracker
This data on vaccination policies is sourced from the Oxford Coronavirus Government Response Tracker (OxCGRT).
This resource is published by researchers at the Blavatnik School of Government at the University of Oxford: Thomas Hale, Anna Petherik, Beatriz Kira, Noam Angrist, Toby Phillips and Samuel Webster.
The tracker presents data collected from public sources by a team of over one hundred Oxford University students and staff from every part of the world.
The data presented here is taken directly from the OxCGRT project; Our World in Data do not track policy responses ourselves, and do not make additions to the tracker dataset.
These charts are regularly updated based on the latest version of the response tracker.
OxCGRT is an ongoing collation project of live data. If you see any inaccuracies in the underlying data, or for specific feedback on the analysis or another aspect of the project please contact OxCGRT team. See the tracker’s notes and guidance on data quality.
The speed at which the first COVID-19 vaccines were developed was extraordinary. We have previously looked into the history of vaccine development. The measles vaccine was found relatively rapidly: it took only 10 years from the discovery of the pathogen to the development of the first vaccine. But for typhoid it took more than a century, and for some diseases for which we’ve known the pathogens for more than a century (like malaria) we still haven’t found an effective vaccine.
The development of a vaccine against COVID-19 has been much faster than the development of any other vaccine. Within less than a year several successful vaccines have already been announced and were approved for use in some countries.
The hope is that even more manufacturers develop vaccines for COVID-19. This will be important because eventually a very large share of the world population needs to receive a COVID-19 vaccine.
Several institutions maintain websites on which they list COVID-19 candidate vaccines that are currently being developed:
- The London School of Hygiene & Tropical Medicine Vaccine Tracker is updated weekly and shows the current stage of each development.
- WHO Vaccine Tracker – The WHO is tracking the COVID-19 candidate vaccines that are under development.
- Milken Institute Vaccine Tracker – The Milken Institute publishes, and regularly updates a tracker of possible treatments and vaccines for COVID-19 that scientists are currently working on.
- New York Times – The NYT tracker includes brief summaries of each development.
You can download the full dataset alongside the detailed source descriptions on GitHub.
Note that other countries have also started vaccination campaigns—we’ll add them to our maps and charts as soon as numbers are verifiable based on public official sources.
We do not include participants in the vaccine arm of clinical trials, as this data is not available for many of the hundreds of trials currently taking place.
Location | Source | Last observation date | Vaccines |
---|---|---|---|
Argentina | Government of Argentina | January 15, 2021 | Sputnik V |
Austria | Ministry of Health | January 17, 2021 | Pfizer/BioNTech |
Bahrain | Ministry of Health | January 16, 2021 | Pfizer/BioNTech, Sinopharm |
Belgium | Sciensano | January 13, 2021 | Pfizer/BioNTech |
Bulgaria | Ministry of Health | January 16, 2021 | Moderna, Pfizer/BioNTech |
Canada | COVID-19 Canada Open Data Working Group | January 16, 2021 | Moderna, Pfizer/BioNTech |
Chile | Department of Statistics and Health Information | January 14, 2021 | Pfizer/BioNTech |
China | National Health Commission | January 13, 2021 | CNBG, Sinovac |
Costa Rica | National Health Commission | January 15, 2021 | Pfizer/BioNTech |
Croatia | Ministry of Health | January 16, 2021 | Pfizer/BioNTech |
Cyprus | Ministry of Health | January 15, 2021 | Pfizer/BioNTech |
Czechia | Ministry of Health | January 13, 2021 | Pfizer/BioNTech |
Denmark | Statens Serum Institut | January 16, 2021 | Moderna, Pfizer/BioNTech |
England | Government of the United Kingdom | January 16, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Estonia | National Health Board | January 17, 2021 | Pfizer/BioNTech |
Finland | THL via Helsingin Sanomat | January 15, 2021 | Pfizer/BioNTech |
France | Ministry of Health | January 16, 2021 | Pfizer/BioNTech |
Germany | Robert Koch Institut | January 15, 2021 | Moderna, Pfizer/BioNTech |
Gibraltar | Government of Gibraltar | January 12, 2021 | Pfizer/BioNTech |
Greece | Ministry of Health | January 16, 2021 | Pfizer/BioNTech |
Guinea | National Health Security Agency | December 30, 2020 | Sputnik V |
Hungary | Government of Hungary | January 16, 2021 | Pfizer/BioNTech |
Iceland | Directorate of Health | December 30, 2020 | Pfizer/BioNTech |
India | Ministry of Health | January 17, 2021 | Covaxin, Covishield |
Ireland | Heath Service Executive | January 13, 2021 | Pfizer/BioNTech |
Israel | Government of Israel | January 17, 2021 | Pfizer/BioNTech |
Italy | Extraordinary commissioner for the Covid-19 emergency | January 17, 2021 | Pfizer/BioNTech |
Kuwait | Ministry of Health | December 28, 2020 | Pfizer/BioNTech |
Latvia | National Health Service | January 16, 2021 | Pfizer/BioNTech |
Lithuania | Ministry of Health | January 16, 2021 | Pfizer/BioNTech |
Luxembourg | Government of Luxembourg | January 14, 2021 | Pfizer/BioNTech |
Malta | Ministry of Health | January 15, 2021 | Pfizer/BioNTech |
Mexico | Secretary of Health | January 16, 2021 | Pfizer/BioNTech |
Netherlands | National Institute for Public Health and the Environment | January 15, 2021 | Pfizer/BioNTech |
Northern Ireland | Government of the United Kingdom | January 16, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Norway | Norwegian Institute of Public Health | January 14, 2021 | Pfizer/BioNTech |
Oman | Ministry of Health | January 15, 2021 | Pfizer/BioNTech |
Poland | Ministry of Health | January 16, 2021 | Pfizer/BioNTech |
Portugal | National Health Service | January 15, 2021 | Pfizer/BioNTech |
Romania | Government of Romania | January 17, 2021 | Pfizer/BioNTech |
Russia | Russian Direct Investment Fund | January 13, 2021 | Sputnik V |
Saudi Arabia | Saudi Health Council | January 17, 2021 | Pfizer/BioNTech |
Scotland | Government of the United Kingdom | January 16, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Serbia | Government of Serbia | January 14, 2021 | Pfizer/BioNTech |
Singapore | Ministry of Health | January 12, 2021 | Pfizer/BioNTech |
Slovakia | Ministry of Health | January 17, 2021 | Pfizer/BioNTech |
Slovenia | National Institute of Public Health, via Sledilnik | January 16, 2021 | Pfizer/BioNTech |
Spain | Ministry of Health | January 15, 2021 | Moderna, Pfizer/BioNTech |
Sweden | Public Health Agency of Sweden | January 10, 2021 | Pfizer/BioNTech |
Switzerland | Federal Office of Public Health | January 14, 2021 | Pfizer/BioNTech |
Turkey | COVID-19 Vaccine Information Platform | January 17, 2021 | Sinovac |
United Arab Emirates | National Emergency Crisis and Disaster Management Authority | January 17, 2021 | Pfizer/BioNTech, Sinopharm |
United Kingdom | Government of the United Kingdom | January 16, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
United States | Centers for Disease Control and Prevention | January 15, 2021 | Moderna, Pfizer/BioNTech |
Wales | Government of the United Kingdom | January 16, 2021 | Oxford/AstraZeneca, Pfizer/BioNTech |
Sign up for regular updates from Our World in Data
→ If you want to keep up-to-date with on our work on COVID-19, and the many other topics we cover you can sign up to our newsletter.